Top in GI: AGA probiotics guidance, telehealth during COVID-19

The American Gastroenterological Association issued new guidance that recommends against the use of probiotics for digestive conditions. It was the top story in gastroenterology last week.

Another top story was about lessons that gastroenterologists from a large private practice have learned during the COVID-19 pandemic on how to provide optimal patient care via telehealth.

Read these and more popular news in gastroenterology below:

AGA does not recommend probiotics for most GI conditions

In newly issued guidelines, the American Gastroenterological Association did not recommend using probiotics for most digestive conditions. Read more.

Telehealth during COVID-19: What one large private GI practice learned

The COVID-19 pandemic has made it critically important to have the option to see a health care provider while remaining safely at home. Enter telehealth, which allows us to see patients remotely. Read more.

Q&A: Diversity in GI improves patient outcomes

Diversity in medicine has demonstrated improvements in access to care among undeserved communities and may positively influence health care delivery, patient outcomes and public policy, according to a report in the American Journal of Gastroenterology. Read more.

Q&A: Zeposia may be efficacious oral therapy for UC

Zeposia (ozanimod, Bristol Myers Squibb) may be an efficacious new oral therapy option with a favorable risk-benefit profile for patients with ulcerative colitis, according to results from the pivotal phase 3 trial True North. Read more.

Curcumin no better than placebo for postoperative Crohn’s recurrence

Oral curcumin was no more effective than placebo for preventing Crohn’s disease recurrence among patients who underwent surgery for Crohn’s, according to study results. Read more.